#504 - Bill Taranto, President at Merck Global Health Innovation Fund
Slice of Healthcare Team
06/17/2025
Episode details
Join us on the latest episode, hosted by Jared S. Taylor!
Our Guest: Bill Taranto, President at Merck Global Health Innovation Fund.
What you’ll get out of this episode:
- Bill Taranto’s Journey: From Johnson & Johnson to leading Merck’s $600M GHI Fund focused on digital health and technology.
- Four Core Investment Areas: Drug discovery, clinical development, supply chain, and patient access/data.
- Portfolio Spotlights: Companies like Npower, Unnatural Products, Aerosafe Global, Cure AI, and Prognos are driving impactful innovation.
- Strategic Value of CVCs: Beyond capital, CVCs offer startups technical expertise, commercial agreements, and long-term support.
- Navigating Market Challenges: Insights on VC pullback, consolidation trends, and advice for startups on sustainable growth.
Watch
Listen
Read More
Driving the Future of Digital Health: Inside Merck’s GHI Fund
In a compelling conversation on the Sliced Healthcare Podcast, Bill Taranto, President of the Merck Global Health Innovation (GHI) Fund, shared how his career journey led to building one of the most forward-thinking corporate venture capital funds in healthcare today.
From Wall Street to Digital Health Pioneer
After starting his career in banking, Taranto transitioned to Johnson & Johnson, where he spent two decades learning the healthcare ecosystem and mastering venture capital. J&J’s directive to “invest in the future of healthcare” shaped his strategy—one that remains core to his leadership today.
In 2010, Merck recruited him to start its venture activity from scratch. Now, 15 years later, the GHI Fund is a $600M evergreen fund with a portfolio of 95 investments, 45 of which are currently active.
Focus Areas of Investment
The GHI Fund strategically invests across four key pillars:
- Drug Discovery & Development
Leveraging AI/ML, novel platforms, and technologies to enhance drug discovery and clinical development—optimizing patient identification, recruitment, and site selection. - Supply Chain Innovation
Creating robust, data-driven solutions to ensure medicines are delivered safely and efficiently, such as the development of control towers for real-time tracking of raw materials and finished products. - Patient Access & Support
Investing in tools like remote monitoring, care navigation, and critical decision support to improve patient outcomes without breaching corporate practice of medicine statutes. - Real-World Evidence & Data
Focusing on advanced analytics and informatics to enhance pre- and post-market data generation for better healthcare decisions.
Portfolio Companies Making an Impact
Taranto highlighted several standout investments:
- Npower: Improving diversity in clinical trial recruitment to meet new FDA mandates.
- Unnatural Products: Utilizing AI-driven engineering in the macrocyclic peptide space for innovative drug discovery.
- Aerosafe Global: Offering cold chain as a service to deliver vaccines safely worldwide, even in extreme climates.
- Cure AI: Enabling early lung cancer detection through AI-driven screening tools.
- Prognos: Harnessing millions of lab records to power clinical diagnostic AI for better decision-making.
The Value of Corporate Venture Capital (CVC)
Taranto emphasized that CVCs like GHI offer more than funding. Startups benefit from:
- Access to technical and research expertise
- Help navigating complex corporate environments
- Opportunities for commercial agreements and early customers
- Industry knowledge and extended distribution networks
- Potential for strategic acquisition
The ultimate value lies in the partnership between Merck and its portfolio companies—aligning business improvements with innovative technology.
Market Realities & Strategic Advice
Addressing the current VC climate, Taranto explained that both CVCs and traditional VCs have pulled back due to market uncertainty, elevated valuations post-COVID, and tightening debt markets.
Merck’s fund, however, can play the long game, thanks to its strong balance sheet. Taranto predicts market improvement by late 2025, with consolidation opportunities growing stronger toward year-end.
For startups, he advises:
- Manage cash carefully and plan for a longer runway.
- Look for merger opportunities to build scale and offer comprehensive solutions.
- Think in terms of building a broader ecosystem, rather than relying on single point solutions.
